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Charnock JC, Dilworth MR, Aplin JD, Sibley CP, Westwood
M, Crocker IP. The impact of a human IGF-II analog ([Leu27]IGF-
II) on fetal growth in a mouse model of fetal growth restriction. Am
J Physiol Endocrinol Metab 310: E24–E31, 2016. First published
November 3, 2015; doi:10.1152/ajpendo.00379.2015.—Enhancing
placental insulin-like growth factor (IGF) availability appears to be an
attractive strategy for improving outcomes in fetal growth restriction
(FGR). Our approach was the novel use of [Leu27]IGF-II, a human
IGF-II analog that binds the IGF-II clearance receptor IGF-IIR in fetal
growth-restricted (FGR) mice. We hypothesized that the impact of
[Leu27]IGF-II infusion in C57BL/6J (wild-type) and endothelial nitric
oxide synthase knockout (eNOS/; FGR) mice would be to enhance
fetal growth and investigated this from mid- to late gestation; 1
mg·kg1·day1 [Leu27]IGF-II was delivered via a subcutaneous min-
iosmotic pump from E12.5 to E18.5. Fetal and placental weights
recorded at E18.5 were used to generate frequency distribution curves;
fetuses 5th centile were deemed growth restricted. Placentas were
harvested for immunohistochemical analysis of the IGF system, and
maternal serum was collected for measurement of exogenously ad-
ministered IGF-II. In WT pregnancies, [Leu27]IGF-II treatment
halved the number of FGR fetuses, reduced fetal(P  0.028) and
placental weight variations (P  0.0032), and increased the numbers
of pups close to the mean fetal weight (131 vs. 112 pups within 1 SD).
Mixed-model analysis confirmed litter size to be negatively correlated
with fetal and placental weight and showed that [Leu27]IGF-II pref-
erentially improved fetal weight in the largest litters, as defined by
number. Unidirectional 14CMeAIB transfer per gram placenta (System
A amino acid transporter activity) was inversely correlated with fetal
weight in [Leu27]IGF-II-treated WT animals (P  0.01). In eNOS/
mice, [Leu27]IGF-II reduced the number of FGR fetuses(1 vs. 5 in the
untreated group). The observed reduction in FGR pup numbers in both
C57 and eNOS/ litters suggests the use of this analog as a means
of standardizing and rescuing fetal growth, preferentially in the
smallest offspring.
fetal growth restriction; insulin-like growth factor; endothelial nitric
oxide synthase knockout; [Leu27]insulin-like growth factor II
FETAL GROWTH RESTRICTION (FGR) affects 3–10% of babies
worldwide and is associated with increased risk of stillbirth,
postnatal disability, and impaired motor and cognitive func-
tions. FGR also has lifelong health implications for affected
babies, with increased associated risk of hypertension, cardio-
vascular disease, stroke, and diabetes in adulthood (1, 2, 3, 35).
Currently, early delivery is the only treatment for FGR, result-
ing in further risks of iatrogenic morbidity and mortality (37).
There are several causes of FGR, including maternal under-
nutrition, fetal chromosomal anomalies, and placental dysfunc-
tion, the last of these being the most common cause in Western
countries. Placental dysfunction has several different pheno-
typic characteristics (41): 1) the placenta often being smaller,
with reduced villous area and thickened exchange barrier (31);
2) reduced vascular complexity and abnormalities in uterine
and fetoplacental blood flow (25); 3) lower activity of nutrient
transporters in the syncytiotrophoblast microvillous and basal
plasma membranes (36); and 4) abnormal placental cell turn-
over, typified by excessive apoptosis and attenuated prolifera-
tion (7, 22).
Normal fetal growth is dependent on interplay between fetal,
placental, and maternal factors. One family of growth factors,
the insulin-like growth factors (IGF-I and IGF-II) and their cell
surface receptors (IGF-IR and IGF-IIR), is known to be critical
regulators of this growth (17). In humans, circulating total
IGF-I in fetal cord blood correlates with birth weight, and
mutations in the IGF-I or IGF-IR genes result in severe FGR
(18). In mice, ablation of IGF-I or IGF-II genes or elimination
of IGF-IR begets severe growth restriction and/or perinatal
lethality (30). Using the placental-specific IGF-II-knockout
mouse (P0), in which a placental-specific promoter of IGF-II
has been deleted, the additional importance of placentally
derived IGF-II on placenta and fetal weight has been verified
(10). IGF-I and IGF-II are mediators of placental cell turnover,
proliferation, survival, and differentiation in vitro and modu-
late fetal growth in utero by promoting nutrient transfer and
placental blood flow (16, 26, 33, 42). Studies in guinea pigs
have confirmed the importance of IGF-I in nutrient partitioning
from mother to fetus and the role of maternal IGF-II in
enhancing placental development and function (38, 40).
Although the roles of IGF-I, IGF-II, and IGF-IR signaling in
the human and animal placenta are affirmed, the significance of
IGF-IIR in mediating IGF signaling is less well defined.
Evidence for signaling through this receptor is accumulating
(14, 15), but classically IGF-IIR has been considered a clear-
ance receptor, trafficking excess IGF-II to lysosomes for deg-
radation. This concept is exemplified in IGF-IIR knockout
mice, which exhibit fetal and placental overgrowth (45), as a
presumed consequence of surplus IGF-II overactivating fetal
IGF-IR.
The development of treatments for FGR is dependent on
suitable animal models in which they may be tested, and a
number of models have been characterized in sheep (4), guinea
pig (6, 28), and rat (43). Recent work on gene knockout and
transgenic mouse models of pregnancy disease suggests that
these may be particularly useful (12). One such model is the
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endothelial nitric oxide synthase knockout (eNOS/) (23),
which may be considered a more amenable model for FGR.
eNOS/ fetuses are 10% smaller than their wild-type (WT)
counterparts, and this is associated with abnormalities in pla-
cental transporter activity and dysregulated utero- and fetopla-
cental blood flow, similar to observations in human FGR (11).
Although systemic administration of IGF-I or -II may be an
appealing approach to address placental insufficiency, ubiqui-
tous tissue expression of IGF receptors may cause off-target
effects. A possible alternative is to enhance the bioavailability
of endogenous IGF already present at the materno-fetal inter-
face. Theoretically, this should be achievable by blocking
IGF-IIR. Previously, we have described methods of influencing
IGF-II signaling in vitro by siRNA knockdown of IGF-IIR and
by the use of an IGF-IIR-specific agonist, [Leu27]IGF-II, to
block IGF-II removal and optimize its availability (21). In
vitro, this approach encourages signaling through IGF-IR,
thereby enhancing mitogenesis and cell survival in placental
villous explants. A previous in vivo study administering
[Leu27]IGF-II to normal pregnant guinea pigs at midgestation
demonstrated modified placental morphology, enhanced ex-
change capacity, and, most importantly, significantly increased
fetal weight at term (whereas IGF-II alone did not) (39). Here,
we hypothesized that the novel treatment of both normal and
FGR mice with [Leu27]IGF-II would potentially increase IGF-
II, therefore enhancing fetal growth in WT litters and improv-
ing weights in the growth-restricted fetuses of pregnant
eNOS/ knockouts.
METHODS
Animals and administration of [Leu27]IGF-II. Experiments were
performed in accordance with the UK Animals (Scientific Procedures)
Act of 1986 under Home Office Licence No. PPL40/3385. The Local
Ethical Review Process of the University of Manchester approved all
protocols. eNOS/ were obtained from Jackson Laboratories (strain
B6.129P2-Nos3tm1Unc/J). Homozygous eNOS/ mice were mated,
and the presence of a copulation plug was denoted as day 0.5 of
pregnancy. C57/BL6J mice, the eNOS/ background strain, were
used as WT mice. Animals had free access to food (Beekay Rat and
Mouse Diet; Bantin & Kingman, Hull, UK) and water and were
maintained on a 12:12-h light-dark cycle at 21–23°C. On embryonic
day (E)12.5, females were anesthetized using isoflurane inhalation
and a 100-l miniosmotic pump (200D; Alzet) surgically inserted
subcutaneously in the upper dorsum. Miniosmotic pumps had previ-
ously been prepared to deliver vehicle (0.1 M HCl) or 1
mg·kg1·day1 [Leu27]IGF-II (human recombinant protein; GroPep)
in 0.1 M HCl for 6 days at a flow rate of 0.51 l/h. [Leu27]IGF-II was
delivered to 26 C57/BL6J dams (199 fetuses), and 25 C57/BL6J dams
(190 fetuses) received vehicle. In a separate experiment, 11 eNOS/
dams (74 fetuses) were treated with [Leu27]IGF-II, and 11 eNOS/
dams (86 fetuses) were given vehicle. All animals were euthanized on
E18.5 by Schedule 1 procedure in accordance with the UK Animals
(Scientific Procedures) Act 1986. Fetuses and placentas were blotted
and weighed. Placentas were halved and fixed in 4% (vol/vol) neutral-
buffered formalin for histological assessment. In animals in which
radioactivity had not been used, maternal and fetal serum were
collected and frozen in liquid nitrogen.
Fetal weight distribution curves. Fetal weight histograms were
constructed as described previously (12), and a nonlinear regression
(Gaussian distribution) analysis was performed. The 5th and 95th
percentile weights were calculated as (Z critical value  SD) 
mean for the former and (Z critical value  SD)  mean for the
latter, where Z critical value  1.645 and SD  standard deviation.
Unidirectional materno-fetal clearance of 14C-MeAIB across the
intact placenta. The clearance across the placenta of 14C-methylami-
noisobutyric acid (MeAIB), a nonmetabolizable substrate for the
placental amino acid transporter system A, was measured across the
intact placenta on E18.5 using an adaptation of the method of Flexner
and Pohl (1941), as described previously (5). Following infusion of
14C-MeAIB, exsanguination of the dam occurred between 1 and 5 min
postinfusion. Fetuses were rapidly collected and assessed for total
radiolabel accumulation and compared with a maternal plasma 14C-
MeAIB disappearance curve generated from current and historical
in-house data. This was constructed from dams on E18.5 (n  109,
group data for C57/BL6J) and fitted to a one-phase exponential decay
model (r2  0.6), as described previously (12). MeAIBKmf
(l·min1·g1 placenta) was calculated as
Kmf
Nx
W
0
x
Cmtdt
where Nx  total radiolabel accumulation (disintegrations/min) by the
fetus at x min after injection of radiolabel into the maternal vein, W 
placental wet weight (g) and equals the time integral of radioisotope
concentration in maternal plasma (disintegrations·min1·l1) from 0 to
x min (taken from the maternal plasma 14C-MeAIB disappearance
curve).
Enzyme-linked immunosorbent assays. ELISAs were performed
according to the manufacturers’ protocols. Human IGF-II ELISAs to
detect [Leu27]IGF-II were performed at a 1:10 dilution (detection
range 0.02–9 ng/ml, intra- and interassay coefficient of variation 
12.7 and 18.0%, respectively; Mediagnost).
Immunohistochemistry. Freshly harvested placental tissues were
fixed in 4% (vol/vol) neutral-buffered formalin at 4°C overnight,
washed in phosphate-buffered saline (PBS), embedded in paraffin
wax, and cut into 5-m serial sections. These were microwaved in 0.1
M sodium citrate buffer for antigen retrieval, and then endogenous
peroxide activity was blocked by placing the slides in methanol
containing 0.4% (vol/vol) HCl and 0.5% (vol/vol) hydrogen peroxide
for 30 min. Tissue sections were washed three times in 0.05 M PBS
and then incubated with 5% BSA to block any nonspecific binding
sites. Sections were incubated with polyclonal rabbit anti-IGF-II (UK
1:100; Abcam, Cambridge), rabbit anti-IGF-IR (UK 1:100; Fisher
Scientific-UK, Loughborough, UK), rabbit anti-IGF-IIR (1:100; R &
D Systems, Abingdon, UK), or rabbit IgG (minus primary antibodies,
for negative controls; DakoCytomation, Ely, UK) overnight at 4°C.
Sections were washed (3  5 min with PBS) and then incubated with
secondary antibody (biotinylated goat anti-rabbit IgG; 1:500 Dako-
Cytomation) for 1 h at room temperature, followed by avidin-perox-
idase (5 g/ml in 0.125 M Tris·HCl, pH 7.6; Sigma-Aldrich, Gilling-
ham, UK) for 30 min at room temperature. Slides were washed in
Tris-buffered saline and incubated for 1–5 min with 0.05% (wt/vol)
diaminobenzidine and 0.015% (vol/vol) hydrogen peroxide (Sigma-
Aldrich). Tissue sections were counterstained with hematoxylin and
visualized by light microscopy (BX41; Olympus UK, London, UK).
Statistical analysis. Generalized linear mixed-model analysis with
Sidak posttest was used to determine the effect of drug treatment on
fetal weight of pups from litters of varying size (P 0.05 was deemed
statistically significant). Data were tested for normality following a
D’Agostino & Pearson normality test and subjected to unpaired t-test
or Mann-Whitney U-test accordingly. Variance within groups was
determined using an F-test of equality of variances (P  0.05).
Correlations were determined by linear regression analysis. All sta-
tistical analyses were carried out using GraphPad Prism 5.03 software.
RESULTS
The IGF-II axis in murine placenta. Previous studies have
documented the presence of IGF-II and IGF-IIR mRNA (18,
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33, 44), but protein localization has been less well defined.
Here, we show that IGF-II is localized throughout the decidua,
the junctional zone, including giant cells and glycogen cells,
and labyrinth, including trophoblast and vessel endothelium
(Fig. 1, A and D). IGF-IR is expressed by giant cells, tropho-
blast, and glycogen cells in the junctional zone (Fig. 1B) and is
also present within labyrinthine trophoblast and the surround-
ing vessels and maternal sinuses (Fig. 1E). IGF-IIR displayed
a similar localization to IGF-IR, including glycogen cells,
trophoblast, labyrinthine trophoblast, and endothelium (Fig. 1,
C and F).
[Leu27]IGF-II treatment reduces fetal and placental weight
variations in WT mice. The delivery of [Leu27]IGF-II to the
maternal circulation was confirmed by analyzing serum from
treated and untreated dams using an ELISA specific for human
IGF-II; only the samples from WT and eNOS/ mothers that
had received [Leu27]IGF-II contained detectable levels of
hIGF-II (WT levels: 42.89 	 11.05 ng/ml, n  4; eNOS/:
28.47 	 13.91 ng/ml, n  3; means 	 SE).
Treatment of WT mice with [Leu27]IGF-II did not alter litter
size (7.3 	 0.4 vs. 7.8 	 0.3, n  25 and 25, respectively;
means 	 SE) or number of fetal resorptions (0.52 	 0.17 vs.
0.69	 0.17). Although [Leu27]IGF-II did not affect mean fetal
weight, population frequency distribution curves revealed that
the distribution of weights was narrowed (kurtosis  0.85 vs.
0.03), with an increase in the number of fetuses close to the
mean weight (131 vs. 112 pups within 1 SD) (Fig. 2A).
Concomitantly, treatment reduced fetal (P  0.028) and pla-
cental weight variations (P  0.003), as assessed by F-test of
equality of variance (Fig. 2, B and C). Treatment also halved
the number of pups with fetal weights below the 5th centile of
the control population (skewness  1.14 vs. 1.22) from 6.3 (n 
11) to 2.5% (n 5). The number of pups with fetal weights above
the 95th centile also decreased from 4.7 (n 9) to 3.0% (n 6),
in line with a normalization effect. Fetal/placental weight ratios, as
a measurement of placental efficiency, were unchanged
([Leu27]IGF-II-treated ratio  15.00 	 0.229, vehicle-treated
ratio  14.94 	 0.404; means 	 SE).
[Leu27]IGF-II improves fetal weight in large litters in WT
mice. Generalized linear mixed-model analyses were per-
formed to assess the effects of different variables, including
litter size and [Leu27]IGF-II treatment, on fetal and placental
weights. The mean weight of both placentas and fetuses from
litters with the largest number of pups (10) was lower that than
of litters with four pups (P  0.05; Fig. 3, A and B). Treatment
with [Leu27]IGF-II increased the mean weight of the fetuses
(P  0.05), but not placentas, from large litters; however,
neither parameter was affected when litter size was small.
Consequently, fetal/placental weight ratios were increased only
in large litters (P  0.05; Fig. 3C).
Placental amino acid transport is inversely correlated with
fetal weight following maternal [Leu27]IGF-II treatment in WT
mice. To assess the impact of [Leu27]IGF-II on placental
function, unidirectional materno-fetal clearance of 14C-MeAIB
(MeAIBKmf) across the placenta, a measure of in vivo system A
amino acid transporter activity, was investigated. Activity was
Fig. 1. IGF-II axis localization in murine placenta. A and D: IGF-II was localized throughout the decidua, junctional zone [giant cells (arrow) and glycogen cells;
A] and labyrinth (trophoblast, arrowhead; vessel endothelium, dashed arrow; D). B and E: IGF-I receptor (IGF-IR) was present throughout the junctional zone
(giant cells, arrowhead; trophoblast, thin arrow; glycogen cells, thick arrow; B) and labyrinthine trophoblast (arrowhead), with strong expression surrounding
vessels and maternal sinuses (dashed arrows) (E). C and F: IGF-IIR displayed a similar localization to IGF-IR, including glycogen cells (thick arrow), trophoblast,
(black arrowhead in C), labyrinthine trophoblast (black arrowheads in F), and endothelium (dashed arrow). Negative staining (minus primary antibody) controls
for junctional zone and labyrinth regions also included. Bars, 100 m.
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not significantly altered following [Leu27]IGF-II treatment;
however, like the variation in birth weight, there was signifi-
cantly less variation in clearance between the litters of treated
animals (F-test P  0.05; Fig. 4A). System A amino acid
transporter activity was inversely correlated with placental
weight in both [Leu27]IGF-II- and vehicle-treated animals,
with smaller pups exhibiting increased transfer per gram pla-
centa (Fig. 4B). An inverse correlation between fetal weight
and system A amino acid transporter activity per gram placenta
was observed only in the [Leu27]IGF-II-treated group (P 
0.01; Fig. 4C).
[Leu27]IGF-II treatment reduces the number of growth-
restricted fetuses in eNOS/ mice. In eNOS/ mice,
[Leu27]IGF-II did not affect mean litter fetal or placental
weight but significantly increased individual fetal weights (P
0.0263; Fig. 5A) and reduced the number of eNOS/ fetuses
below the eNOS/ population 5th centile by threefold [8.8
(n  5) vs. 2.6% (n  1)]. Treatment also reduced the number
below the 5th centile of the WT distribution by 9% (35–44%)
(Fig. 5B). Placental weights and the variation of fetal weights
around the population mean were unchanged ([Leu27]IGF-II-
treated placental weight  0.0854 	 0.0012, vehicle-treated
placental weight  0.0873 	 0.0015; means 	 SE).
DISCUSSION
The importance of IGF-II signaling in mouse fetal growth is
well described, with both total and placental specific IGF-II
knockout transgenic animals associated with impaired fetal and
placental development (9, 10). Since systemic administration
of exogenous IGF-II may have off-target effects, we investi-
gated an alternative approach to optimize fetal growth via
constant [Leu27]IGF-II infusion in an effort to enhance endog-
enous IGF-II availability. As reported in the guinea pig (32),
we have shown that it is possible to deliver a constant infusion
of the IGF-IIR-specific analog [Leu27]IGF-II systemically to
Fig. 2. [Leu27]IGF-II’s effects on fetal weight varia-
tion and no. of fetal growth-restricted (FGR) pups in
normal mice. Leu27: n  26 pregnancies, 199 fetuses;
vehicle: n  25, 180 fetuses. A: C57 population
distribution curves for individual fetal weights of
[Leu27]IGF-II- (solid line) and vehicle-treated mice
(dashed line). Treatment halved the number of pups
with 5th centile fetal weights from 6.3 to 2.5%
(skewness 1.14 vs. 1.22) and reduced the number of
95th centile animals from 4.7 to 3%. Individual fetal
and placental weights showed reduced variation in
treated animals (when tested by F-test of equality of
variances). B and C: fetal (P 0.028; B) and placental
weights (0.0032; C).
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pregnant mice, without impact on litter size or resorptions.
Moreover, with apparent benefits to fetal weight, specifically
with regard to the most vulnerable (smallest) pups within the
litters in normal and growth-restricted mouse pregnancies, this
study holds implications for the further understanding and
optimization of fetal growth in utero.
To manipulate the IGF axis at the cellular level, we first
confirmed the presence of its constituent components within
the mouse placenta. Endogenous IGF-II as well as both IGF
receptors, IGF-IR and IGF-IIR, were present throughout the
murine placenta, including labyrinthine cells, where nutrient
exchange occurs. These findings complement those of others,
who have described similar IGF-II mRNA and protein distri-
butions, alongside colocalization of IGF-IR and IGF-IIR prin-
cipally in mouse trophoblast and vascular endothelium (44).
Therefore, theoretically at least, enhancing endogenous IGF-II
is an attractive strategy to stimulate placentally driven fetal
growth.
We demonstrated that constant subcutaneous infusion of
[Leu27]IGF-II into WT pregnant mice from midgestation on-
ward reduces the number of fetuses with weights below the 5th
centile of the study population. Although fetal sex difference
was not considered, we showed [Leu27]IGF-II to have its
greatest effect in preferentially increasing fetal weights within
the smallest, lightest WT fetuses. Because normal animals
would be expected to exhibit optimal fetal growth, it could be
reasoned that any beneficial effects of treatment might be
restricted to fetuses of greater in utero compromise, for exam-
ple, those under nutritionally stressed circumstances. There-
fore, we concluded that pups in large litters compete with
varying effectiveness for maternal resources, producing a
range of weights in the offspring, and any positive impact on
smaller pups can restrict intake by larger pups in the same
litter, thus normalizing fetal weights. Within our data, a general
inverse relationship between litter size and fetal and placental
weights was noted. In the absence of direct changes in placen-
tal weight, we envisage this enhancement to be through an
exaggeration in functional capacity.
Previous work in WT and P0 knockout mice has shown that
an increased placental efficiency, as shown by an increased
fetal/placental weight ratio, is associated with increased
MeAIBKmf (8, 9, 10). This suggests that increased placental
system A amino acid transporter activity at least partially
underpins the increased placental efficiency. Therefore, we
investigated the relationship between MeAIBKmf and placen-
tal and fetal weight in the presence and absence of
[Leu27]IGF-II by analysis of unidirectional materno-fetal
clearance of MeAIB (MeAIBKmf) across placentas as a
measure of system A amino acid transport activity. Our
data show a strong inverse correlation between MeAIBKmf
and placental weight in both the presence and absence of the
hormone analog; this is consistent with previous studies
linking an increase in placental efficiency with enhanced
system A activity. Interestingly, although there was no
correlation between MeAIBKmf and fetal weight, which was
expected since the increased placental efficiency would tend
to drive fetal growth to a constant level across a litter, there
was an inverse correlation in the [Leu27]IGF-II treated
animals. This latter result is intriguing but difficult to
decipher. With the relative interplay between placental and
fetal weights uncertain, even in WT mice, the uncoupling of
Fig. 3. Mean weight/ratio for litters according to size of litter (nos. of pups) and
generalized linear mixed-model analysis of [Leu27]IGF-II effects. A: mean
placental weight decreased with increased no. of pups/litter (10 or 9 vs. 4 pups,
P  0.05). [Leu27]IGF-II had no effect on mean placental weight. B: mean
fetal weight decreased with increased no. of pups/litter (10 vs. 4 pups, P 
0.05). [Leu27]IGF-II increased mean fetal weight in largest litters (10 pups).
C: fetal/placental weight ratio increased in large litters (9 vs. 4, P  0.05).
[Leu27]IGF-II increased this ratio in the largest litters (10 pups). *P  0.05.
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this relationship by [Leu27]IGF-II by either its effects on
amino acid transport or a shift in allocation of resources is
a possibility, but one requiring further investigation.
In support of our findings in the mouse, Sferruzzi-Perri et al.
(39) have previously demonstrated beneficial effects of
[Leu27]IGF-II infusion in pregnant guinea pigs from midges-
tation onward. Resulting increases in fetal weight were attrib-
uted to enhanced placental functional activities, with increased
system A activity and glucose transfer per gram of placenta.
Consistent with the concept that [Leu27]IGF-II can normalize
(and arguably optimise) fetal growth, we demonstrated a re-
duction in litter variability in system A transport in the mouse,
mirroring its impact on placental and fetal weights and poten-
tially explaining it.
In light of improved fetal weights in constitutively small
offspring of WT mice, we investigated for the first time the
effects of maternal [Leu27]IGF-II infusion in a pregnant mouse
model of FGR (eNOS/). [Leu27]IGF-II increased eNOS/
fetal weights, reducing numbers below the 5th centile, akin to
that of wild-type mice. Although [Leu27]IGF-II failed to re-
store mean fetal weights to WT levels, the clinical relevance of
such an outcome should not be overlooked, as preferential
growth in the smallest offspring could increase fetal weights
above critical centiles for both viability and in utero program-
ming, thereby having a significant impact on fetal, neonatal,
and longer-term well being in humans. In defining mecha-
Fig. 4. System A amino acid transporter activity in [Leu27]IGF-II- (n  7, 51
fetuses) and vehicle-treated (n  8, 60 fetuses) C57 mice. A: unidirectional
14CMeAIB transfer per gram placenta (kmf) (median 	 interquartile range).
Variation was significantly reduced in [Leu27]IGF-II-treated mice (P  0.05).
B: transfer (kmf) was inversely correlated with placental weight in both groups
([Leu27]IGF-II: P  0.011, r2  0.198; vehicle: P  0.0007, r2  0.186).
C: transfer (kmf) is inversely correlated with fetal weight in [Leu27]IGF-II-
treated animals only (P  0.01, line of best fit presented).
Fig. 5. [Leu27]IGF-II’s effects on fetal weight in endothelial nitric oxide
synthase (eNOS) mice (means 	 SE). A: population distribution curves for
individual [Leu27]IGF-II-treated eNOS (solid line), vehicle-treated eNOS
(dashed line), and vehicle-treated wild-type (WT) (C57; gray line) mice.
Treatment reduced the no. of 5th centile eNOS fetuses and the no. of 5th
centile fetuses of the C57 population. B: individual fetal weights were in-
creased (P  0.0263).
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nisms, it is suggested that [Leu27]IGF-II, like IGF-II, may
promote uterine angiogenesis and vascular remodelling (24,
39), improving blood flow and nutrient delivery. Although not
assessed in this study, the eNOS/ mouse exhibits altered
uterine vascular function, which may be improved through
[Leu27]IGF-II exposure (41).
There are a number of signaling mechanisms by which
[Leu27]IGF-II may elicit either maternal or fetal effects. Pre-
vious work by our group (21, 27), using human placental
explants, indicates that likely saturation of IGF-IIR by
[Leu27]IGF-II may enhance endogenous IGF-II bioavailability
and increase signaling through IGF-IR, augmenting its well-
documented growth-promoting properties. Within that study,
decreased IGF-IIR expression increased an IGF-II-mediated
impact on mitosis and placental cell survival. Alongside these
observations and the knowledge that IGF-IIR knockout mice
elicit fetal overgrowth, these findings imply a role for IGF-IIR
blockade in stimulating tissue growth via increasing IGF-II
bioavailability and in turn IGF-IR activation (29). Furthermore,
the effects on maternal adiposity described by Sferruzzi-Perri
et al. (39), which were similar to those observed previously
following IGF-I (but not IGF-II) treatment, also support the
concept of endogenous IGF-II displacement to enhance its
interaction with IGF-IR. In addition, IGF-IIR may itself have
direct signaling capabilities, rather than acting exclusively as a
clearance receptor (21). Further in vitro studies have demon-
strated the capacity of [Leu27]IGF-II signaling via IGF-IIR to
stimulate activation of MARK3/1, resulting in trophoblast
migration and cell survival (32). Therefore, although signaling
pathways within pregnant mice remain uncertain, both direct
and indirect IGF receptor interactions may be balanced within
the placenta to ensure appropriate placental and fetal growth.
In summary, we have defined a reduction in FGR pups in
WT and eNOS/ litters exposed to a maternal exogenous
analog of IGF-II. Under normal circumstances, we propose that
the IGF axis is already optimized for any given fetus, and as
such [Leu27]IGF-II-treatment has little or no positive effect on
normal mice, as IGF-IIR is saturated. By contrast, in compro-
mised, inadequately growing fetuses (i.e., smaller pups where
IGF-II is potentially restricted), [Leu27]IGF-II acts to promote
availability of endogenous IGF-II, restoring placental suffi-
ciency and standardizing fetal growth, rescuing the FGR phe-
notype.
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